Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeOstial CorporationOstial Corporation Reaches 15,000 FLASH™ System Units Sold

Ostial Corporation Reaches 15,000 FLASH™ System Units Sold

Ostial Corporation (Ostial), is a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions.  Today the company announced they have reached a new milestone, passing the mark of 15,000 commercial units sold of its FLASH™ Aorto-Ostial Angioplasty System (FLASH System) in over 300 hospitals across the United States. FLASH is the first and only dual balloon-based system designed for use in aorto-ostial angioplasty in coronary and peripheral cases.

“Aorto-ostial lesions are notoriously difficult vascular interventions due to their challenging location and complex vessel morphology,” stated William Lombardi, MD, Clinical Professor of Medicine, Director of Complex Coronary Artery Disease Therapies and Attending Physician at the University of Washington Medical Center in Seattle, Washington. “FLASH is an optimal treatment for these high-risk lesions as it allows me to confidently treat the entire diseased area, while maintaining access for future interventions.”

The FLASH System is an innovative dual-balloon angioplasty catheter designed to help overcome challenges of aorto-ostial stenting by delivering true 360° stent apposition at the ostium. The novel technology employs a non-compliant distal balloon that post-dilates and anchors the system while an outer compliant contouring proximal balloon allows the operator to precisely position the catheter at the aorto-ostium, gently flaring the stent to the ostium wall. Total stent apposition with FLASH optimizes patient outcomes while improving reaccess for future interventions.1

“This is a significant achievement for our company, and I would like to thank our small yet growing team for reaching this important milestone,” stated Jon Bohane, General Manager and Chief Operating Officer of Ostial Corporation. “We are pleased to offer physicians and their patients the only aorto-ostial balloon that achieves complete and efficient lesion coverage.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy